Southern Cross Health Insurance (SCHI) has confirmed it does not fund ongoing treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD) once a diagnosis has been made, clarifying how its policies apply to neurodevelopmental conditions and mental health exclusions. In late 2025, the insurer wrote to paediatricians explaining how existing policy wording should be applied to ADHD and ASD. The communication followed queries from providers seeking certainty on which post-diagnostic services could be billed to Southern Cross.
In a letter to patients’ families, a Wellington paediatrician said his practice had been advised that Southern Cross’ policy was to “exclude coverage for ADHD and ASD, as they classify these conditions as mental health disorders.” He told families that “it is important to note that Dr ... does not share this classification,” indicating a difference between some clinical views and the insurer’s classification approach. Southern Cross chief sales and marketing officer Regan Savage said the November correspondence did not introduce a new exclusion but clarified how existing terms should be applied. “This was not a new directive or change in classification, but confirmation of how our policy needs to be applied. We issued the clarification as we had become aware of differing levels of understanding of our policy amongst providers, and our need to ensure our affiliated providers can administer our policy entitlements correctly,” Savage said, as reported by RNZ. Under the clarified approach, Southern Cross funds consultations to assess possible ADHD or ASD where the person has not already received a diagnosis, subject to standard terms and conditions. Once a diagnosis is confirmed, further assessments, consultations, and related treatment are not covered.
Savage said the position reflects how Southern Cross designs its benefits. “Southern Cross Health Insurance policies generally exclude cover for treatment of mental health conditions and these conditions are classified as mental and neurodevelopmental disorders under internationally recognised classification systems,” Savage said. He added that the insurer’s core products are structured mainly around acute or unexpected health events rather than long-term care. Cover was usually limited to “short-term or unexpected health issues. Conditions like ADHD can involve complex, life-long care such as medication, therapy, and specialist support which creates significant and predictable costs. Covering costs like this through insurance would mean much higher premiums for all members, making health insurance less affordable overall,” Savage said.
Some policies include limited mental health-related benefits, such as funding for general practice and nursing consultations and Pharmac-subsidised prescriptions, but ongoing ADHD and ASD management falls outside standard cover. For health insurers and reinsurers, the stance raises questions about where to set boundaries for long-duration mental health and neurodevelopmental costs within medical insurance products and how those limits are communicated to members and intermediaries.
The clarification comes as families often seek private assessment because of pressure on public services. A Wellington parent, who does not hold a Southern Cross policy, said the public pathway for ADHD assessment and support is under strain. The parent said the public system was “already totally under-resourced, which is why people go private,” and described situations where families “reach crisis point with their kids – they know there’s something wrong, but can’t get into the public system for a diagnosis, which then opens to the door to some level of support and understanding of what’s happening for their kids. They can be in survival mode for months before someone will see them for an assessment – there are long waiting lists in both private and public systems, but at least you know you’ll get to the finish line with private.”
The parent told RNZ that diagnosis is often only the beginning of engagement with services. For many, “the very beginning of the journey” starts once ADHD or ASD is confirmed. She added: “For ADHD, it can take months and many appointments to get medication right. For ASD, I imagine there are a huge amount of secondary issues they need professional support with.” For insurers, this care pattern highlights the difference between finite diagnostic costs and open-ended treatment needs and may influence how cover limits and exclusions are explained at the proposal and advice stages.
ADHD New Zealand is calling for a larger role for publicly funded services to avoid diagnosis and treatment being dependent on personal finances or private cover. Spokesperson Sarah Hogan said some people are able to obtain assessment through health insurance but many are not. “But health insurance is beyond the reach of many people with ADHD, so an equitable response requires publicly funded diagnosis and treatment,” Hogan told RNZ. She said that while people can access general mental health services through the public system, there is no dedicated stream “specifically for ADHD,” despite ongoing health needs that can accompany the condition.
“When people with ADHD experience mental health issues, it can often be unclear how this may be related to their ADHD and this may be different for different people. The public system does not fund mental health services specifically for ADHD, but people with ADHD may access the same publicly funded mental health services that other New Zealanders access. This is not always adequate,” Hogan said. For insurers, any expansion in public provision may influence expectations about what sits in core health insurance benefits and the degree to which policies are expected to respond to long-term ADHD and ASD care.
From February 2026, changes to regulatory and funding rules will widen who can diagnose and initiate medical treatment for ADHD, with potential implications for health service demand and insurance portfolios. Following decisions by Medsafe and Pharmac, general practitioners and nurse practitioners will be able to start medical treatment for adults with ADHD, rather than requiring a recommendation from a paediatrician or psychiatrist or a specialist-issued first prescription. Pharmac acting director of advice and assessment Catherine Epps said the change “will mean that over time, more GPs and nurse practitioners will be able to diagnose and start adults on treatment for ADHD.” For children and adolescents, nurse practitioners working within child health or mental health services will also be able to diagnose and commence treatment.
Medsafe group manager Chris James said the reform makes greater use of existing primary care skills. “We have a workforce of highly experienced general practitioners and nurse practitioners, a number of whom are already working closely with specialists to treat patients with ADHD. Implementing this change will mean they can do this work more quickly and efficiently without needing to wait for approval from a specialist. It’s important we ensure a high quality of ADHD assessment, and that people can expect to receive appropriate care and support. We have been working closely with sector representatives to develop a clinical framework which will set out principles for diagnosing and treating ADHD, including the appropriate clinical care required of healthcare practitioners,” James said. The change was initially proposed for July 2025 but was deferred to February 2026 after consultation responses raised concerns about methylphenidate supply and the need for more time for GPs and nurse practitioners to build further clinical expertise.
Recent New Zealand survey data indicate that about 3% of people aged 5 and over have been diagnosed with ADHD, with higher rates among children than adults and among males than females. Just over half of those with an ADHD diagnosis were also identified as disabled in the survey. For autism, around 2% of New Zealanders aged 5 and over have a diagnosis, with children more likely than adults to be diagnosed and 70% of those with autism also identified as disabled. Academic and dispensing data point to a substantial gap between estimated ADHD prevalence in adults and the proportion receiving medication. Research has also found that Māori and Pacific peoples are less likely to receive ADHD medicines, with differences emerging from early childhood, including lower medication rates for tamariki Māori screened at age four compared with non-Māori peers.
International studies have linked untreated ADHD with poorer mental and physical health outcomes, higher mortality, and reduced life expectancy. Reinsurance-sector analysis has reported higher ADHD prevalence in prison populations and significant social and economic costs at a population level. For New Zealand insurers, these patterns intersect with product strategy, underwriting, and claims. Growing awareness, expanded diagnostic capacity, and persistent inequities may lead to more ADHD and ASD disclosures at application and claim stage. At the same time, health policies that exclude ongoing treatment for these conditions may face continued scrutiny from advisers, group schemes, and institutional buyers as public policy moves to broaden access to diagnosis and medicines. In that context, Southern Cross’ clarification sits within a wider industry discussion about how to distinguish between insurable, episodic medical events and long-term neurodevelopmental and mental health support, and how to set and explain those boundaries to the market.
